Caraco Pharmaceutical Laboratories, Ltd. Announces Settlement of Ethyol(R) ANDA Patent Litigation

Share Name	Share Symbol	Market	Type
Caraco Pharmaceutical Laboratories, Ltd. Common Stock	AMEX:CPD	AMEX	Ordinary Share

Share Name

Share Symbol

Market

Type

Caraco Pharmaceutical Laboratories, Ltd. Common Stock

AMEX:CPD

AMEX

Ordinary Share

Price Change

% Change

Share Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

0.00

Caraco Pharmaceutical Laboratories, Ltd. Announces Settlement of Ethyol(R) ANDA Patent Litigation

03/08/2009 5:22am

PR Newswire (US)

Caraco (AMEX:CPD)
Historical Stock Chart

From Jun 2019 to Jun 2024

DETROIT, Aug. 3 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announces today that it has executed a settlement agreement with MedImmune, stipulating the dismissal of the lawsuits filed in the United States District Court for the District of Maryland regarding the submission of an Abbreviated New Drug Application (ANDA) for a generic version of Ethyol . Under the settlement agreement, MedImmune grants Caraco a license to certain patents, permitting Caraco to continue marketing a generic version of Ethyol in the United States. The settlement resolves the entirety of the litigations between the parties. The terms of the settlement are confidential. Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers. Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements. DATASOURCE: Caraco Pharmaceutical Laboratories, Ltd. CONTACT: Thomas Versosky, Caraco Pharmaceutical, +1-313-556-4150 Web Site: http://www.caraco.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

CPD Caraco Pharmaceutical Laboratories, Ltd. Common Stock